DOYLESTOWN, PA (December 1, 2005) The Quigley Corporation (NASDAQ: QGLY),
announced today Quigley Pharma's QR-441 compound sprayed on respiratory mask
air filters has been tested against avian influenza virus (H5N1) and human
influenza virus (H3N2). The QR-441 impregnated masks prevented up to 99% of the
viruses whereas the masks not treated with QR-441 had the ability to prevent up
to 90% of the viruses passing through. More important and significant findings
show that the QR-441 compound proved to deactivate the live viruses passing
through these filters. Deactivation of live viruses in a range of 95.1 to 98.7%
were observed in these studies.
The study took place at Retroscreen Virology, Queen Mary's School of Medicine
and Dentistry, University of London, in the UK, under the direction of
Professor John Oxford and Dr. Rob Lambkin. Under GLP (Good Laboratory Practice)
compliance conditions, commercially available respiratory facemasks were
impregnated with the company's all-natural, anti-viral QR-441 formula.
Quigley Pharma's Charles A. Phillips, senior vice president said, "If
there is an outbreak of Avian flu in our U.S. human population, initially it
will be easier to distribute the formula as a spray to be used on the exterior
of commercially available masks than to develop and distribute a new style mask
using the compound. In an emergency situation, the spray formula's increased
ability to stop the virus from penetrating these masks may help reduce viral
transmission." Phillips continued, "In addition, we can develop new
types of "active" masks utilizing the same technology designed for
viral use."
Availability of this spray to the public could be insured through The Quigley
Corporation's extensive Cold-Eeze retail distribution system already in place.
The Company is pursuing several development plans with all relevant government
agencies and private organizations for various levels of approval for:
- Government healthcare and poultry workers for a possible avian influenza
outbreak preparedness programs.
- Industry poultry-care workers for avian influenza outbreak situations
requiring the slaughter and disposal of infected birds and cleanup operations.
- Emergency medical type masks, such as surgical or procedure masks, as
well as isolation face masks.
- Homeland Security applications for high-risk situations.
The Quigley Corporation is the leading developer and marketer of diversified
health products. The Company's proven success in launching first-in-category
health solutions supports the Pharma subsidiary in its efforts to develop
strong pharmaceutical compounds targeting diverse conditions such as diabetes
and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug
Administration or any other regulatory agency will grant an IND for human study
or take any other action to allow the aforementioned compound to be marketed.
Furthermore, no claim is made that the potential medicine discussed here is
safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a
diversified natural health medical science company. Its Cold Remedy segment is
a leading marketer and manufacturer of the COLD-EEZEŽ family of lozenges, gums
and sugar free tablets clinically proven to cut the common cold nearly in half.
COLD-EEZE customers include leading national wholesalers and distributors, as
well as independent and chain food, drug and mass merchandise stores and
pharmacies. The Quigley Corporation has four (4) wholly owned subsidiaries.
Darius International markets health and wellness products through its wholly
owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two
FDA approved facilities to manufacture COLD- EEZEŽ lozenges as well as fulfill
other contract manufacturing opportunities. Quigley Pharma Inc.
(http://www.QuigleyPharma.com) conducts research in order to develop and
commercialize a pipeline of patented botanical and naturally derived
prescription drugs.
Certain statements in this press release are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995 and involve known and unknown risk, uncertainties and other factors
that may cause the company's actual performance or achievements to be
materially different from the results, performance or achievements expressed or
implied by the forward-looking statement. Factors that impact such
forward-looking statements include, among others, changes in worldwide general
economic conditions, changes in interest rates, government regulations, and
worldwide competition.
